A Phase 2 interventional study of Placebo and BIBF 1120 in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 8 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-06.
Sponsored by Boehringer Ingelheim · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 8th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 1st registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:
First Affiliated Hospital of Wenzhou Medical University
Ages 40+
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2010.
This study's enrollment of 50 is close to the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 49 across the 16 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim: 1 open now, 3 under way, 1 of them phase 3. Of 31 finished, 26 (84%) have results posted.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2010, is one of 7 in phase 2, and was the 1st registered.
Boehringer Ingelheim’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2010.
1 of the studies testing nintedanib in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07583589First Affiliated Hospital of Wenzhou Medical UniversityNintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 36 in Idiopathic Pulmonary Fibrosis:
This tab as a report to print or save as PDF → With an account.
To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis (IPF), with and without pirfenidone background treatment.
To assess pharmacokinetics of BIBF 1120 in Japanese patients, with and without pirfenidone background treatment.
To assess pharmacokinetics of pirfenidone in Japanese patients, alone and in combination with BIBF 1120 treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Being treated with any of the following concomitant medications.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose for cohort 1
Drug: BIBF 1120
Middle dose for cohort 2
Drug: BIBF 1120
High dose for cohort 3
Drug: BIBF 1120
Placebo for cohort 1,2,3
Drug: Placebo
Placebo BID for cohort 1,2,3
50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
Drug-related Adverse Events
The number of patients with drug-related adverse events stratified according to pirfenidone use in each group
Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days
AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone
AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone
AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)
AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.
Time frame: Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)
Time frame: Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)
AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.
Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)
Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)
AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.
Time frame: Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)
Time frame: Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)
AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.
Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)
Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Withdrawal Due to Adverse Event
Number of patients prematurely discontinued from trial medication due to adverse event.
Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days
Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background
Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background
Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days
Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background
Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background
Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
Change From Baseline in Pulse Rate
Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)
Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)
Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)
Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
Lung Function Measurement: Forced Vital Capacity (FVC)
Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)
Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
Time frame: baseline and day 35
| Milestone | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Started | 12 | 6 | 8 | 24 |
| Completed | 12 | 6 | 8 | 20 |
| Not completed | 0 | 0 | 0 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 |
The number of patients with drug-related adverse events stratified according to pirfenidone use in each group
| participants | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Patients with Pirfenidone (N = 5, 4, 4, 13) | 1 | 0 | 0 | 7 |
| Patients without Pirfenidone (N = 7, 2, 4, 11) | 1 | 0 | 1 | 3 |
AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
| ng*h/mL | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|
| AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone | 33.7 ± 165 | 115 ± 32.4 | 218 ± 58.3 |
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
| ng/mL | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|
| Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone | 9.09 ± 173 | 20.0 ± 64.5 | 39.7 ± 68.1 |
AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
| ng*h/mL | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|
| AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone | 67.9 ± 16.7 | 86.0 ± 62.7 | 149 ± 18.0 |
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose
| ng/mL | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|
| Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone | 10.9 ± 50.3 | 13.8 ± 113 | 23.5 ± 27.2 |
AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.
| ng*h/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast) | 28900 ± 30.7 | 34400 ± 36.3 | 45800 ± 26.6 | 32500 ± 21.2 |
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)
| ng/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast) | 11300 ± 22.1 | 11900 ± 28.9 | 14600 ± 41.5 | 11200 ± 26.6 |
AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.
| ng*h/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast) | 28800 ± 6.85 | 34300 ± 39.9 | 35000 ± 32.2 | 35900 ± 21.8 |
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)
| ng/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast) | 12000 ± 23.1 | 12800 ± 44.3 | 15300 ± 51.1 | 12600 ± 27.2 |
AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.
| ng*h/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch) | 56600 ± 25.8 | 72800 ± 40.7 | 84100 ± 11.4 | 60900 ± 22.9 |
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)
| ng/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch) | 13500 ± 19.9 | 14600 ± 20.9 | 15100 ± 19.5 | 12900 ± 30.2 |
AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.
| ng*h/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch) | 47000 ± 13.6 | 71000 ± 40.8 | 71500 ± 19.1 | 63600 ± 27.7 |
Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)
| ng/mL | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch) | 10700 ± 18.8 | 12000 ± 37.3 | 12100 ± 10.7 | 12500 ± 23.0 |
Number of patients prematurely discontinued from trial medication due to adverse event.
| participants | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| With Pirfenidone (N= 5, 4, 4, 13) | 0 | 0 | 0 | 2 |
| Without Pirfenidone (N = 7, 2, 4, 11) | 0 | 0 | 0 | 2 |
Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background
| participants | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Alanine aminotransferase increased | 0 | 0 | 0 | 2 |
| Aspartate aminotransferase increased | 0 | 0 | 0 | 2 |
| Blood creatine phosphokinase increased | 0 | 0 | 0 | 1 |
| Gamma-glutamyltransferase increased | 0 | 0 | 0 | 1 |
Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background
| participants | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Hypothyroidism | 0 | 0 | 0 | 1 |
| Transaminases increased | 0 | 0 | 0 | 1 |
Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| mmHg | Placebo | BIBF 1120 150 mg |
|---|---|---|
| DBP | 0.5 ± 13.3 | -0.8 ± 10.8 |
| SBP | 1.3 ± 19.2 | 2.5 ± 14.4 |
Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| bpm | Placebo | BIBF 1120 150 mg |
|---|---|---|
| Change From Baseline in Pulse Rate | -2.5 ± 15.4 | 1.9 ± 13.6 |
Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| mL/min/mmHg | Placebo | BIBF 1120 150 mg |
|---|---|---|
| Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco) | -1.131 ± 1.397 | -0.707 ± 2.005 |
Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| % predicted | Placebo | BIBF 1120 150 mg |
|---|---|---|
| Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco) | -4.660 ± 8.020 | -1.193 ± 5.948 |
Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| Liter | Placebo | BIBF 1120 150 mg |
|---|---|---|
| Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1) | -0.021 ± 0.107 | 0.036 ± 0.078 |
Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| Liter | Placebo | BIBF 1120 150 mg |
|---|---|---|
| Lung Function Measurement: Forced Vital Capacity (FVC) | -0.081 ± 0.175 | 0.050 ± 0.086 |
Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.
| % predicted | Placebo | BIBF 1120 150 mg |
|---|---|---|
| Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC) | -2.311 ± 5.193 | 1.432 ± 2.671 |
Collected over after the first drug intake until 28 days from the last treatment administration, up to 60 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/12 (0%) | 4/12 (33.3%) |
| BIBF 1120 50 mg | — | 0/6 (0%) | 0/6 (0%) |
| BIBF 1120 100 mg | — | 0/8 (0%) | 4/8 (50%) |
| BIBF 1120 150 mg | — | 1/24 (4.2%) | 14/24 (58.3%) |
| Event | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 0/6 | 0/8 | 1/24 |
| Event | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/12 | 0/6 | 0/8 | 5/24 |
| VomitingGastrointestinal disorders | 0/12 | 0/6 | 0/8 | 5/24 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/6 | 0/8 | 4/24 |
| StomatitisGastrointestinal disorders | 0/12 | 0/6 | 1/8 | 1/24 |
| NasopharyngitisInfections and infestations | 0/12 | 0/6 | 1/8 | 2/24 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/12 | 0/6 | 1/8 | 0/24 |
| ErythemaSkin and subcutaneous tissue disorders | 0/12 | 0/6 | 1/8 | 0/24 |
| Abdominal discomfortGastrointestinal disorders | 1/12 | 0/6 | 0/8 | 1/24 |
| Abdominal pain upperGastrointestinal disorders | 1/12 | 0/6 | 0/8 | 0/24 |
| Gastritis erosiveGastrointestinal disorders | 1/12 | 0/6 | 0/8 | 0/24 |
Treated set: all patients who received study medication and were documented to have taken at least one dose of investigational treatment
| Age, Continuous(years) | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg | Total |
|---|---|---|---|---|---|
| Mean | 64.1 ± 10.3 | 66.7 ± 2.9 | 67.5 ± 7.4 | 64.7 ± 8.5 | 65.2 ± 8.2 |
| Sex: Female, Male(Participants) | Placebo | BIBF 1120 50 mg | BIBF 1120 100 mg | BIBF 1120 150 mg | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 4 | 8 | 15 |
| Male | 11 | 4 | 4 | 16 | 35 |
The record gives a start of May 2010 and a primary completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 10 months after primary completion. A results delay was requested in May 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib
Idiopathic Pulmonary Fibrosis →